Journal of Biomolecular Research & Therapeutics

Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA

Publications

• Research Article   
  Manassantin A and B are Potential Therapeutic Agents for Treating Nonalcoholic Fatty Liver Disease
  Author(s): John Min, Sin-Hee Han, Ae-Jin Choi, Faridoddin Mirshahi, Shunlin Ren, Jason D. Kang, Phillip B. Hylemon, Hae-Ki Min* and Arun J. Sanyal*
  
  Manassantin (MNS) has been reported to have various biological activities including repression of Hypoxia-Inducible Factor 1 (HIF-1), anti-inflammatory, and anti-plasmodial properties. Here, we investigated whether MNS has the potential to serve as a therapeutic agent for treating Non-Alcoholic Fatty Liver Disease (NAFLD) via regulation of hepatic AMPK and ERK1/2, gp130/Stat3, inflammation, and autophagy pathways. In NAFLD patients, AMPKα (Thr172) phosphorylation levels were suppressed, whereas ERK1/2 phosphorylation levels were increased. In addition, IL-6 levels were directly correlated with ERK1/2 activation and were inversely related to decreases in AMPKα (Thr172) phosphorylation. MNS increased activation of AMPKα by increasing cellular AMP: ATP ratio, decreased ERK1/2 and PKC-θ phosphorylation, and decreased p62 and LC3 protei.. View more»
  

  DOI: 10.35248/2167-7956.22.11.196

  Abstract HTML PDF